Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANZAR phase III first-line NSCLC study
jRCT2031220612Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2023
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan, durvalumab, carboplatin and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-Free Survival and Overall Survival. Started Feb 2023; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031220612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220612.